Neuroceptor

Neuroceptor is a private biotechnology company dedicated to discovering and developing novel treatments for chronic pain and other central nervous system (CNS) disorders. The company was founded in 2021 by Dr. David Bredt, a prominent neuroscientist who previously led neuroscience research at Janssen and Eli Lilly. Neuroceptor’s core technology focuses on the modulation of AMPA receptors, which are critical for fast excitatory synaptic transmission in the brain. By specifically targeting the interaction between AMPA receptors and their regulatory proteins, known as TARPs, the company seeks to achieve therapeutic effects with high precision and reduced side effects. Currently in the pre-clinical stage, Neuroceptor is backed by leading life sciences investors such as MPM Capital. The company's approach represents a significant shift in neuropharmacology, moving toward synapse-specific modulation.